All Stories

  1. First-in-man assessment of plaque rupture by polarization-sensitive optical frequency domain imagingin vivo
  2. Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound
  3. Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study)
  4. A novel method to assess coronary artery bifurcations by OCT: cut-plane analysis for side-branch ostial assessment from a main-vessel pullback
  5. Positive remodeling at 3 year follow up is associated with plaque free coronary wall segment at baseline: A serial IVUS study
  6. Intracoronary thrombus on optical coherence tomography in a patient with variant angina: Treatment and follow-up
  7. Excess mortality in women compared to men after PCI in STEMI: An analysis of 11,931 patients during 2000–2009
  8. Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: Results from the ATHEROREMO-IVUS study
  9. Modified T-Technique With Bioresorbable Scaffolds Ensures Complete Carina Coverage
  10. Optical Coherence Tomography-Guided Bifurcation Stenting of a Coronary Artery Dissection
  11. P-010 Optical Coherence Tomography (OCT) Before and After Flowdiverter Treatment in Basilar Dolichoectasia
  12. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)
  13. The impact of Fourier-Domain optical coherence tomography catheter induced motion artefacts on quantitative measurements of a PLLA-based bioresorbable scaffold
  14. ASSOCIATION OF WALL SHEAR STRESS WITH VASCULAR HEALING RESPONSE BY OCT 5 YEARS AFTER BIORESORBABLE SCAFFOLD IMPLANTATION
  15. ACUTE ANGIOGRAPHIC AND SIX-MONTH CLINICAL OUTCOMES AFTER IMPLANTATION OF EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLDS IN LONG LESIONS (>32MM)
  16. ASSESSMENT OF CO-REGISTRATION BETWEEN 3D ANGIOGRAPHY AND IVUS. AN IN VIVO FEASABILITY STUDY
  17. OPTICAL COHERENCE TOMOGRAPHY ASSESSMENT OF THE 5-YEAR VASCULAR HEALING RESPONSE FOLLOWING IMPLANTATION OF THE EVEROLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLD
  18. HIGH-SENSITIVITY TROPONIN T IN RELATION TO CORONARY PLAQUE CHARACTERISTICS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: RESULTS OF THE ATHEROREMO-IVUS STUDY
  19. Effect of temperature and fixation on the optical properties of atherosclerotic tissue: a validation study of an ex-vivo whole heart cadaveric model
  20. Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
  21. Standing on Solid Ground?
  22. CRT-605* Everolimus Eluting Bioresorbable Vascular Scaffolds for Treatment of Patients Presenting with ST-Segment Elevation Myocardial Infarction, BVS STEMI FIRST Study
  23. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study
  24. Semi-automated Quantification of Fibrous Cap Thickness in Intracoronary Optical Coherence Tomography
  25. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study
  26. TCT-429 Short- and intermediate- term clinical outcomes after implantation of everolimus-eluting bioresorbable scaffold in complex lesions : a prospective single-arm study - ABSORB Expand trial
  27. TCT-254 Everolimus Eluting Bioresorbable Vascular Scaffolds In Patients With ST-Segment Myocardial Infarction. Safety Feasibility and Acute Performance
  28. Determinants of high cardiovascular risk in relation to plaque-composition of a non-culprit coronary segment visualized by near-infrared spectroscopy in patients undergoing percutaneous coronary intervention
  29. Culotte stenting with bioabsorbable everolimus-eluting stents
  30. Quantitative Optical Coherence Tomography Tissue-Type Imaging for Lipid-Core Plaque Detection
  31. Residual atherothrombotic material after stenting in acute myocardial infarction — An optical coherence tomographic evaluation
  32. Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography
  33. Bioresorbable scaffold in myocardial infarction: Has the time come?
  34. Health-related quality of life in the elderly three years after percutaneous coronary intervention
  35. Optical coherence tomography for evaluation of coronary stentsin vivo
  36. Association of neointimal morphology by optical coherence tomography with rupture of neoatherosclerotic plaque very late after coronary stent implantation.
  37. In-stent neoatherosclerosis: are first generation drug eluting stents different than bare metal stents? An optical coherence tomography study
  38. Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study—TROFI trial
  39. Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment
  40. Traumatic Coronary Artery Dissection
  41. Invasive Imaging of Bioresorbable Coronary Scaffolds – A Review
  42. A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients
  43. Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study
  44. Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated ...
  45. Online 3-Dimensional Rendering of Optical Coherence Tomography Images for the Assessment of Bifurcation Intervention
  46. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the A...
  47. Calcified Nodules
  48. TCT-290 Vascular tissue reaction to acute malapposition in human coronary arteries: sequential assessment with optical coherence tomography
  49. TCT-304 Neoatherosclerosis And Impaired Vascular Healing Are Associated With Clinical Presentation Late After Coronary Stent Implantation. An Optical Coherence Tomography Study
  50. Errata: Frequency domain multiplexing for speckle reduction in optical coherence tomography
  51. Five-Year Optical Coherence Tomography Follow-Up of an Everolimus-Eluting Bioresorbable Vascular Scaffold
  52. Frequency domain multiplexing for speckle reduction in optical coherence tomography
  53. In-Stent Neoatherosclerosis
  54. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study
  55. The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3)
  56. Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment
  57. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures
  58. Interstudy reproducibility of the second generation, Fourier domain optical coherence tomography in patients with coronary artery disease and comparison with intravascular ultrasound: a study applying automated contour detection
  59. Optical Coherence Tomography: Potential Clinical Applications
  60. OCT in Coronary Bifurcations
  61. Evaluation of a Dedicated Everolimus Coated Side Branch Access (SBA) System
  62. Differences in Neointimal Thickness Between the Adluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold
  63. Response to Letter Regarding Article, “Delayed Coverage in Malapposed and Side-Branch Struts With Respect to Well-Apposed Struts in Drug-Eluting Stents: In Vivo Assessment With Optical Coherence Tomography”
  64. THREE-DIMENSIONAL RECONSTRUCTION OF IMPLANTED CORONARY STENTS APPLYING OPTICAL COHERENCE TOMOGRAPHY IMAGING
  65. Usefulness of the SYNTAX Score to Predict “No Reflow” in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
  66. Plaque Compositional Syntax Score
  67. VASCULAR RESPONSE OF THE SEGMENTS ADJACENT TO THE PROXIMAL AND DISTAL EDGES OF THE ABSORB EVEROLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLD: 6 MONTHS AND 1 YEAR FOLLOW-UP ASSESSMENT. A SERIAL INTRAVASCULAR ULTRASOUND RADIOFREQUENCY DATA ANALYSIS FROM ...
  68. Distance of Lipid Core–Rich Plaques From the Ostium by NIRS in Nonculprit Coronary Arteries
  69. Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies
  70. Wavelength multiplexing for FD-OCT speckle averaging
  71. Vascular Tissue Reaction to Acute Malapposition in Human Coronary Arteries
  72. Beta blocker therapy is associated with reduced depressive symptoms 12months post percutaneous coronary intervention
  73. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography
  74. 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold
  75. A drug-eluting stent, accidentally removed as late as 1½ years after implantation
  76. Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography
  77. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts
  78. Long-term tissue coverage of a biodegradable polylactide polymer–coated biolimus-eluting stent: Comparative sequential assessment with optical coherence tomography until complete resorption of the polymer
  79. Acute Coronary Syndrome in 3 Dimensions
  80. Three-Dimensional Reconstruction of the Post-Dilated ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold in a True Bifurcation Lesion for Flow Restoration
  81. Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first
  82. Invasive coronary imaging in animal models of atherosclerosis
  83. Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography
  84. Delayed Coverage in Malapposed and Side-Branch Struts With Respect to Well-Apposed Struts in Drug-Eluting Stents
  85. Invasive imaging technologies
  86. 3-Dimensional optical frequency domain imaging for the evaluation of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction
  87. The diagnostic value of intracoronary optical coherence tomography
  88. Relation between plaque type and dissections at the edges after stent implantation: An optical coherence tomography study
  89. Assessment of Coronary Atherosclerosis Progression and Regression at Bifurcations Using Combined IVUS and OCT
  90. Pitfalls in Plaque Characterization by OCT
  91. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application
  92. 6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm
  93. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial
  94. Healing of a coronary artery dissection detected by intravascular ultrasound and optical coherence tomography
  95. Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease
  96. NIRS and IVUS for Characterization of Atherosclerosis in Patients Undergoing Coronary Angiography
  97. Principles of Intra-Coronary Optical Coherence Tomography
  98. Retrospective image-based gating of intracoronary optical coherence tomography: implications for quantitative analysis
  99. Witnessed Coronary Plaque Rupture During Cardiac Catheterization
  100. First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography
  101. AS-112 Stent Edge Assessment Using a Multi-Modality Imaging Approach: Angiography, IVUS And OCT
  102. HIGH SPEED INTRA-CORONARY OPTICAL FREQUENCY DOMAIN IMAGING: IMPLICATIONS FOR THREE-DIMENSIONAL RECONSTRUCTION AND QUANTITATIVE ANALYSIS
  103. SERIAL ANALYSIS OF THE MALAPPOSED AND UNCOVERED STRUTS OF THE NEW GENERATION OF EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD USING OPTICAL COHERENCE TOMOGRAPHY
  104. FATE OF SIDE BRANCHES AT 6 AND 12 MONTHS AFTER IMPLANTATION OF BIORESORBABLE VASCULAR SCAFFOLDING DEVICES: ASSESSMENT WITH 3-DIMENSIONAL OPTICAL COHERENCE TOMOGRAPHY
  105. SIX MONTH CLINICAL OUTCOMES FOLLOWING THE IMPLANTATION OF THE BIORESORBABLE EVEROLIMUS ELUTING VASCULAR SCAFFOLD IN VESSELS SMALLER OR LARGER THAN 2.5 MM
  106. Six-month clinical follow-up of the tryton side branch stent for the treatment of bifurcation lesions
  107. Intravascular ultrasound radiofrequency analysis after optimal coronary stenting with initial quantitative coronary angiography guidance: an ATHEROREMO sub-study
  108. Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT
  109. Comparison between transmural and non-transmural infarction and the area at risk using T2 weighted imaging
  110. Comparison of adenosine magnetic resonance perfusion imaging with invasive coronary flow reserve and fractional flow reserve in patients with suspected coronary artery disease
  111. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial
  112. Dedicated everolimus-eluting side branch access system: XIENCE SBA
  113. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds
  114. Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis
  115. Intracoronary Optical Coherence Tomography and Histology at 1 Month and 2, 3, and 4 Years After Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model
  116. In Vivo 3D Distribution of Lipid-Core Plaque in Human Coronary Artery as Assessed by Fusion of Near Infrared Spectroscopy–Intravascular Ultrasound and Multislice Computed Tomography Scan
  117. A Comparison of the Conformability of Everolimus-Eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents
  118. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial
  119. Optical coherence tomography
  120. Reproducibility of coronary Fourier domain optical coherence tomography: quantitative analysis of in vivo stented coronary arteries using three different software packages
  121. 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side Branches by Bioresorbable Vascular Scaffolds
  122. Tomografía de coherencia óptica de segunda generación en la práctica clínica. La adquisición de datos de alta velocidad muestra una reproducibilidad excelente en pacientes tratados con intervenciones coronarias percutáneas
  123. First-in-Man Clinical Use of Combined Near-Infrared Spectroscopy and Intravascular Ultrasound
  124. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment
  125. Combined optical coherence tomography and intravascular ultrasound radio frequency data analysis for plaque characterization. Classification accuracy of human coronary plaques in vitro
  126. Rheolytic versus aspiration thrombectomy in acute st-segment elevation myocardial infarction judged by OCT
  127. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial
  128. Monitoring In Vivo Absorption of a Drug-Eluting Bioabsorbable Stent With Intravascular Ultrasound-Derived Parameters
  129. REPRODUCIBILITY OF IN-VIVO CORONARY FOURIER DOMAIN OPTICAL COHERENCE TOMOGRAPHY
  130. EVALUATION OF SIDE BRANCH OPENING USING THREE DIMENSIONAL VISUALIZATION OF NEW GENERATION OPTICAL COHERENCE TOMOGRAPHY AFTER BIOABSORBABLE EVEROLIMUS ELUTING STENT IMPLANTATION
  131. DOES THE SECOND GENERATION OCT IMPROVE SAFETY AND FEASIBILITY IN CLINICAL PRACTICE? A SINGLE CENTER EXPERIENCE
  132. THE FIRST IN HUMAN CLINICAL USE OF A COMBINED NEAR INFRARED SPECTROSCOPY AND INTRAVASCULAR ULTRASOUND CATHETER TO IDENTIFY AND CHARACTERISE INTRACORONARY PLAQUE (SAVOIR STUDY)
  133. INTRACORONARY OPTICAL COHERENCE TOMOGRAPHY (OCT) AND HISTOLOGY 2, 3 AND 4 YEARS AFTER IMPLANTATION OF BIORESORBABLE EVEROLIMUS-ELUTING STENTS IN A PORCINE CORONARY MODEL: AN ATTEMPT TO DECIPHER THE HUMAN OCT IMAGES IN THE ABSORB TRIAL
  134. Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs
  135. Intravascular ultrasound: Assessment of atherosclerosis
  136. Multi-modality intra-coronary plaque characterization: A pilot study
  137. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process
  138. Atherosclerotic tissue characterization in vivo by optical coherence tomography attenuation imaging
  139. First use in patients of a combined near infra-red spectroscopy and intra-vascular ultrasound catheter to identify composition and structure of coronary plaque
  140. Second-Generation Optical Coherence Tomography in Clinical Practice. High-Speed Data Acquisition is Highly Reproducible in Patients Undergoing Percutaneous Coronary Intervention
  141. Three-dimensional visualization of intracoronary thrombus during stent implantation using the second generation, Fourier domain optical coherence tomography
  142. Fully automatic three-dimensional quantitative analysis of intracoronary optical coherence tomography
  143. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis
  144. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study
  145. Imaging atherosclerotic plaque composition with intracoronary optical coherence tomography
  146. Compositional volumetry of non-calcified coronary plaques by multislice computed tomography: an ex vivo feasibility study
  147. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach
  148. Optical coherence tomography patterns of stent restenosis
  149. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy
  150. Virtual histology and optical coherence tomography: from research to a broad clinical application
  151. Reproducibility of quantitative optical coherence tomography for stent analysis
  152. Comparación cuantitativa ex vivo e in vivo de las dimensiones del lumen medidas por tomografía de coherencia óptica y ecografía intravascular en arterias coronarias humanas
  153. Quantitative Ex Vivo and In Vivo Comparison of Lumen Dimensions Measured by Optical Coherence Tomography and Intravascular Ultrasound in Human Coronary Arteries
  154. A multicentre evaluation of the safety of intracoronary optical coherence tomography
  155. First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era?
  156. Incomplete Stent Apposition and Delayed Tissue Coverage Are More Frequent in Drug-Eluting Stents Implanted During Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Than in Drug-Eluting Stents Implanted for Stable...
  157. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses
  158. Optical Coherence Tomography to Guide Treatment of Chronic Occlusions?
  159. In Vivo Assessment of High-Risk Coronary Plaques at Bifurcations With Combined Intravascular Ultrasound and Optical Coherence Tomography
  160. Intracoronary optical coherence tomography and the evaluation of stents
  161. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
  162. Assisted circulation using the TandemHeart® during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG
  163. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis A substudy of the ABSORB clinical t...
  164. The TandemHeart®, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience
  165. A novel approach to quantitative analysis of intravascular optical coherence tomography imaging
  166. An automated approach to quantify volumetric coronary plaque composition by multi-slice computed tomography: An ex-vivo feasibility study
  167. Optical Coherence Tomography Findings in Very Late (4 Years) Paclitaxel-Eluting Stent Thrombosis
  168. A novel approach for quantitative analysis of intracoronary optical coherence tomography: High inter-observer agreement with computer-assisted contour detection
  169. Assessment of Culprit and Remote Coronary Narrowings Using Optical Coherence Tomography With Long-Term Outcomes
  170. Comprehensive Assessment of Coronary Artery Stenoses
  171. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results
  172. Optical coherence tomography assessment of vulnerable plaque rupture: predilection for the plaque ‘shoulder’
  173. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD
  174. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
  175. Diagnosis and treatment of coronary vulnerable plaques
  176. Comparison of Diagnostic Accuracy of 64-Slice Computed Tomography Coronary Angiography in Women Versus Men With Angina Pectoris
  177. From Postmortem Characterization to the In Vivo Detection of Thin-Capped Fibroatheromas: The Missing Link Toward Percutaneous Treatment
  178. Optical coherence tomography
  179. Current Diagnostic Modalities for Vulnerable Plaque Detection
  180. Optical Coherence Tomography in Cardiovascular Research
  181. Three-dimensional and quantitative analysis of atherosclerotic plaque composition by automated differential echogenicity
  182. Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis
  183. Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation
  184. In vivo relationship between compositional and mechanical imaging of coronary arteries
  185. Distal Left Main Coronary Disease Is a Major Predictor of Outcome in Patients Undergoing Percutaneous Intervention in the Drug-Eluting Stent Era
  186. Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies
  187. Plaque Composition and its Relationship With Acknowledged Shear Stress Patterns in Coronary Arteries
  188. Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease
  189. Acute recoil in sirolimus eluting stent: real time, in vivo assessment with optical coherence tomography
  190. Visualization of the Vulnerable Plaque
  191. Clinical imaging of the vulnerable plaque in the coronary arteries: new intracoronary diagnostic methods
  192. In vivo Variability in Quantitative Coronary Ultrasound and Tissue Characterization Measurements with Mechanical and Phased-array Catheters
  193. Optical Coherence Tomography Findings at 5-Year Follow-Up After Coronary Stent Implantation
  194. “Full metal jacket” (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions
  195. Nuevas tendencias en la evaluación de la placa vulnerable mediante técnicas de cateterismo
  196. New Insights Towards Catheter-Based Identification of Vulnerable Plaque
  197. Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease With Paclitaxel-Eluting Stents
  198. Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With Diabetes Mellitus (from the RESEARCH and T-SEARCH Registries)
  199. Late Angiographic Stent Thrombosis (LAST) Events With Drug-Eluting Stents
  200. Methodological considerations and approach to cross‐technique comparisons using in vivo coronary plaque characterization based on intravascular ultrasound radiofrequency data analysis: insights from the Integrated Biomarker and Imaging Study (IBIS)
  201. Endothelial Progenitor Cell Capture by Stents Coated With Antibody Against CD34
  202. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population
  203. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation
  204. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
  205. Geometrical validation of intravascular ultrasound radiofrequency data analysis (Virtual Histology) acquired with a 30 MHz boston scientific corporation imaging catheter
  206. Diagnosis of Vulnerable Plaques in the Cardiac Catheterization Laboratory
  207. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
  208. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients
  209. 1006-62 Forward looking optical coherence tomography: A potential tool to visualize the total chronic occlusion
  210. 884-6 Incidence of vulnerable plaques in humans: Assessment with 3-D intravascular palpography
  211. The Short-Lived Promise of the Radioactive Stent
  212. Catheter-Based Closure of a Coronary Aneurysm
  213. Local Drug Delivery Using Coated Stents: New Developments and Future Perspectives
  214. Optical coherence tomography
  215. New Devices in Interventional Cardiology and Atherosclerotic Disease
  216. Intravascular Palpography for High-Risk Vulnerable Plaque Assessment
  217. Sonotherapy, antirestenotic therapeutic ultrasound in coronary arteries: The first clinical experience
  218. Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy
  219. Evaluation of coronary remodeling after Sirolimus-Eluting stent implantation by serial Three-Dimensional intravascular ultrasound
  220. P2250 Low incidence of subacute stent thrombosis after sirolimus-eluting stent implantation in daily practice - results from the rapamycin eluting stent evaluated at Rotterdam hospital (RESEARCH) registry
  221. Sirolimus-eluting stent for treatment of in-stent restenosis: One-year angiographic and intravascular ultrasound follow-up
  222. The impact of sirolimus-eluting stents on the outcome of patients with bifurcation lesions
  223. Subacute stent thrombosis after sirolimus-eluting stent implantation in daily practice: Results from theRapamycinEluting-Stent Evaluated at Rotterdam Hospital (Research) registry
  224. Sirolimus-eluting stents for treatment of in-stent restenosis in the real world: Preliminary results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry
  225. Sirolimus-eluting stent for treatment of complex in-stent restenosis
  226. Angiographic findings of the multicenter randomized study with the sirolimus-eluting bx velocity balloon-expandable stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size
  227. Fate of side branches after coronary arterial sirolimus-eluting stent implantation
  228. Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL)
  229. A new intracoronary measurement catheter, MetriCath, compared to intravascular ultrasound and quantitative coronary angiography in a stented porcine coronary model
  230. No delayed restenosis at 18 months after implantation of sirolimus-eluting stent
  231. Routine intracoronary beta-irradiation. Acute and one year outcome in patients at high risk for recurrence of stenosis
  232. Ten years after introduction of intravascular ultrasound in the catheterization laboratory: tool or toy?
  233. High shear stress after successful balloon angioplasty is associated with restenosis and target lesion revascularization
  234. Incidence of incomplete stent apposition at six month follow-up in the multi center RAVEL trial
  235. Sirollmus inhibits restenosis irrespective of the vessel size: a subanalysis of the multicenter RAVEL trial
  236. Are sirolimus-eluting stents inducing vascular remodeling? A subgroup analysis of 3D-intravascular ultrasound in the RAVEL trial
  237. El estudio ravel. Reestenosis del cero por ciento: ¡un sueño del cardiólogo hecho realidad!
  238. “Edge Effect” of 32 P Radioactive Stents Is Caused by the Combination of Chronic Stent Injury and Radioactive Dose Falloff
  239. Stent development and local drug delivery
  240. Randomized Comparison of Coronary Stent Implantation Under Ultrasound or Angiographic Guidance to Reduce Stent Restenosis (OPTICUS Study)
  241. Geographical miss during catheter-based intracoronary beta-radiation: incidence and implications in the BRIE study
  242. Value of coronary stenotic flow velocity acceleration on the prediction of long-term improvement in functional status after angioplasty
  243. Intracoronary ultrasound imaging
  244. Serial intravascular ultrasound and quantitative coronary angiography after self-expandable wallstent coronary artery implantation
  245. Distal Embolization
  246. Reproducibility of neointima quantification with motorized intravascular ultrasound pullback in stented coronary arteries
  247. Coronary Stent Implantation in a Septal Perforator Artery
  248. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy
  249. Observer-related variability in IVUS measurements after stenting
  250. IVUS analysis of the acute and long‐term stent result using motorized pullback: Intraobserver and interobserver variability
  251. IVUS analysis of the acute and long-term stent result using motorized pullback: Intraobserver and interobserver variability
  252. Dobutamin-Streßechokardiographie zur Beurteilung des postinterventionellen Ergebnisses nach intrakoronarer Stentimplantation
  253. Quantitative changes in reference segments during IVUS‐guided stent implantation: Impact on the criteria for optimal stent expansion
  254. Quantitative changes in reference segments during IVUS-guided stent implantation: Impact on the criteria for optimal stent expansion
  255. Impact of target lesion calcification on coronary stent expansion after rotational atherectomy
  256. Assessment of intraindividual variability of coronary flow reserve in angiographically normal coronary arteries in transplant recipients: a study with intracoronary doppler and intravascular ultrasound
  257. Effects of Tacrolimus and Cyclosporine on the Coronary Microcirculation After Heart Transplantation: A Prospective Study With Serial Intracoronary Flow Measurements
  258. Interaction of the wallstent with the coronary artery during a longterm follow-up: morphological assessment by serial intravascular ultrasound with a motorized pullback system
  259. Intraindividual variability of coronary flow reserve in heart transplant recipients with angiographically normal coronary arteries, a study with intracoronary doppler and ultrasound
  260. One balloon approach for optimized Palmaz-Schatz stent implantation: The MUSCAT trial
  261. One balloon approach for optimized Palmaz‐Schatz stent implantation: The MUSCAT trial
  262. Coronary aneurysm after bailout stent implantation: Diagnosis of a false lumen with intravascular ultrasound
  263. Serial Follow-up After Optimized Ultrasound-Guided Deployment of Palmaz-Schatz Stents
  264. Coronary plaque morphologic characteristics early and late after heart transplantation: In vivo analysis with intravascular ultrasonography
  265. 951-72 Intravascular Ultrasound Guided Optimized Emergency Coronary Palmaz Schatz Stent Placement without Post Procedural Systemic Anticoagulation
  266. 720-6 Stenting for Progressive Dissection During PTCA: Clinical, Angiographic and Intravascular Ultrasound Criteria to Define a Low-risk Group not Requiring Subsequent Anticoagulation
  267. 731-3 Remodelling of Coronary Arteries After Balloon Angioplasty: In Vivo Documentation in Patients Using Consecutive Intravascular Ultrasound
  268. Ultrasound guidance of Palmaz-Schatz intracoronary stenting with a combined intravascular ultrasound balloon catheter.
  269. Intravascular ultrasound assessment of the balloon-expandable Palmaz-Schatz coronary stent
  270. Optical Coherence Tomography
  271. Vascular Brachytherapy
  272. New Coronary Imaging in Acute Coronary Syndrome
  273. Analysis of Radiofrequency Ultrasound Signals